A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).

Conditions

• Chronic Leukemia Myelogenous

Eligibility Criteria

Sex

ALL

Age

20 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Bosulif — DRUG
  chronic myelogenous leukemia patients

Study Details

The purpose of this study is to look at how safe and effective is bosulif in routine clinical practice. This study is seeking for participants who are: 1. Patients who are being treated\* or will be treated with Bosulif according to it's local product document under routine clinical practice (\*Patients who initiated Bosulif treatment within one year before consent) 2. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. All participants in this study will receive bosulif. All participants who have entered this study should meet the usual prescribing criteria for bosulif as per the LPD. The participants will be treated with bosulif under routine clinical practice in Korea. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective. In this study all treatment and checking of the patients will be done as per the study doctor. The study can be performed in Korean health care centers where bosulif is prescribed to treat CML after the patients have agreed to take part in the study.

Key Dates

Start date

Jan 20, 2025

Status verified

Apr 2026

Primary completion

Jun 1, 2028

Completion

Jun 1, 2028

Study Design

Enrollment

600 participants (estimated)

Arms

• Arm: Patients with newly diagnosed CP Ph+ CML
  Patients newly-diagnosed with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML)

Primary Outcome Measure

Incidence of AEs [ Time Frame: From the date of bosulif treatment completion until index period (Between 30 Dec 2022 and 29 Dec 2028) ]

Central Contacts

• Pfizer CT.gov Call Center
  1-800-718-1021
  [email protected]

Locations (1)

Find similar trials in New York, NY